Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction - A meta analysis of 7 prospective clinical studies

International Journal of Cardiology

Volumn 155, Issue 1, 2012, Pages 33-38

  Fu, Mingqiang ^a   Zhou, Jingmin ^a   Sun, Aijun ^a   Zhang, Shuning ^a   Zhang, Chunyu ^a   Zou, Yunzeng ^a   Fu, Michael ^b   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACEI; Heart failure; Meta analysis; Preserved systolic function

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL;

AGED; ALL CAUSE MORTALITY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; FEMALE; HEART FAILURE; HEART FAILURE WITH PRESERVED HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONOTHERAPY; MORTALITY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; SYSTEMATIC REVIEW;

EID: 84859917835     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.081     Document Type: Review

References (40)

1. Cohn JN, Johnson G. Heart-Failure with Normal Ejection Fraction-the V-Heft Study. Circulation 1990;81(2):48-53.
2. Dougherty AH, Naccarelli GV, Gray EL, et al. Congestive Heart-Failure with Normal Systolic Function. Am J Cardiol 1984;54(7):778-82.
3. Francis CM, Caruana L, Kearney P, et al. Open Access Echocardiography in Management of Heart-Failure in the Community. BMJ 1995;310(6980):634-6.
4. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355(3):251-9.
5. Badano LP, Albanese MC, De Biaggio P, et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. J Am Soc Echocardiogr 2004;17(3):253-61.
6. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular Systolic function - Epidemiology clinical characteristics and prognosis. J Am Coll Cardiol 2004;43(3):317-27.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17(1):1-12.
8. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
9. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997;134(2): 188-95.
10. Philbin EF, Rocco TA, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: Clinical features, outcomes, and the use of angiotensinconverting enzyme inhibitors. Am J Med 2000;109(8):605-13.
11. Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 2003;17(2):133-9.
12. Grigorian LG, Roman AV, Ramos PM, et al. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: A long-term follow-up study. J Card Fail 2006;12(2):128-33.
13. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27(19):2338-45.
14. Tribouilloy C, Rusinaru D, Leborgne L, et al. Prognostic impact of angiotensinconverting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 2008;101(5):639-44.
15. Yip GWK, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008;94(5):573-80.
16. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101(17):2118-21.
17. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001;88(5):530-3.
18. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet 2003;362(9386):777-81.
19. Moutinho MAE, Colucci FA, Alcoforado V, et al. Heart failure with preserved ejection fraction and systolic dysfunction in the community. Arq Bras Cardiol 2008;90(2):145-50.
20. Elshaer F, Hassan W, Fawzy ME, et al. The prevalence, clinical characteristics, and prognosis of diastolic heart failure: a clinical study in elderly saudi patients with up to 5 years follow-up. Congest Heart Fail 2009;15(3):117-22.
21. McDonald K. Diastolic heart failure in the elderly: Underlying mechanisms and clinical relevance. Int J Cardiol 2008;125(2):197-202.
22. Lenzen MJ, Reimer WJMSO, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25(14):1214-20.
23. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and Outcomes of Hospitalized Patients With Heart Failure and Reduced vs Preserved Ejection Fraction - A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009;73(10):1893-900.
24. Galderisi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 2005;3:9.
25. Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000;47(2):274-83.
26. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993;87(4):1328-39.
27. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25(5):563-75.
28. Goodfriend TL, Elliott ME, Catt KJ. Drug therapy - Angiotensin receptors and their antagonists. N Engl J Med 1996;334(25):1649-54.
29. Iusuf D, Henning RH, van Gilst WH, et al. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008;585(2-3): 303-12.
30. Akuzawa N, Nakamura T, Kurashina T, et al. Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 1998;11(6 Pt 1):697-707.
31. Nagai M, Horikoshi K, Izumi T, et al. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004;18(5):353-62.
32. Porteri E, Rodella L, Rizzoni D, et al. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Press 2005;14(3):184-92.
33. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83(6):1849-65.
34. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72.
35. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15(1):36-43.
36. Kawamura M, Imanashi M, Matsushima Y, et al. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol 1992;19(8):547-53.
37. Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101(8):844-6.
38. Garg R, Yusuf S. Overview of Randomized Trials of Angiotensin-Converting Enzyme-Inhibitors on Mortality and Morbidity in Patients with Heart-Failure. JAMA 1995;273(18):1450-6.
39. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28(20):2539-50.
40. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.